Agency Information Collection Activities; Announcement of Office of Management and Budget Approval; Testing Communications on Medical Devices and Radiation-Emitting Products, 18558 [2014-07325]
Download as PDF
<![CDATA[
18558
Federal Register / Vol. 79, No. 63 / Wednesday, April 2, 2014 / Notices
development efforts provide tailored
resource support to Senior Legal
Helplines (SLH) and Model Approaches
to Statewide Legal Assistance Systems
(Model Approaches) projects across the
country. Model Approaches grants
promote the creation of legal services
delivery systems that incorporate SLHs
(and other low-cost service delivery
mechanisms) into the broader tapestry
of Title III–B legal services, and other
available legal resources. Specifically,
the TA grant directed to SLHs provides
resource support for various aspects of
helpline legal service delivery,
including the development of reporting/
data collection systems, case
management systems, targeting and
outreach strategies, and integration
strategies that incorporate SLHs into the
broader tapestry of legal service delivery
in each Model Approaches state. The
TA grant directed to the systems
enhancement objectives of Model
Approaches Phase I and Phase II
projects provides resource support on
the development of needs and capacity
assessments, reporting/data collection
systems and outcomes measures used to
determine the impact of legal services,
and the development of legal service
delivery standards/guidelines that
promote quality and consistent
statewide legal service delivery.
II. Justification for The Exception to
Competition
As with the grants comprising the
National Legal Resource Center, it is
important to assess the effectiveness of
TA grants in helping states meet
increasing challenges in the
development and maintenance of ‘‘high
capacity’’ statewide legal service
delivery systems. To this end, ACL
would like to accomplish two goals this
year: (1) Obtain stakeholder input on the
resource support needs of legal and
aging/disability service providers across
the country and the ability to meet those
needs through focused TA grants; and
(2) establish how best to direct the
current objectives of the TA grants
towards advancing anticipated ACL FY
15 activities related to elder rights and
elder abuse prevention.
within the approved scope and budget
of the grant. Areas that will be evaluated
include:
A. Project Relevance & Current Need
B. Approach
C. Budget
D. Project Impact
E. Organizational Capacity
V. Application and Submission
Requirements
A. SF 424—Application for Federal
Assistance
B. SF 424A—Budget Information
C. Separate Budget Narrative/
Justification
D. SF 424B—Assurances. Note: Be
sure to complete this form according to
instructions and have it signed and
dated by the authorized representative
(see item 18d of the SF 424).
E. Lobbying Certification
F. Program narrative—no more than
10 pages.
G. Work Plan
H. Incumbent grantees will be
required to access the non-competing
application kit in GrantSolutions.gov to
submit all materials for this application.
VI. Application Review Information
Applications will be objectively
reviewed by Federal staff utilizing the
criteria listed above in Section III.
VII. Agency Contact
For further information or comments
regarding this program expansion
supplement, contact Omar Valverde,
U.S. Department of Health and Human
Services, Administration for
Community Living, Administration on
Aging, Office of Elder Rights, One
Massachusetts Avenue NW.,
Washington, DC 20001; telephone (202)
357–3515; fax (202) 357–3549; email
omar.valverde@acl.hhs.gov.
Dated: March 27, 2014.
Kathy Greenlee,
Administrator and Assistant Secretary for
Aging.
[FR Doc. 2014–07340 Filed 4–1–14; 8:45 am]
BILLING CODE 4154–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
tkelley on DSK3SPTVN1PROD with NOTICES
Food and Drug Administration
IV. Evaluation Criteria
Information previously provided in
semi-annual reports, as well as
information in the non-competing
extension application will be
considered to determine satisfactory
progress of the grantee project and
ensure that proposed activities are
Agency Information Collection
Activities; Announcement of Office of
Management and Budget Approval;
Testing Communications on Medical
Devices and Radiation-Emitting
Products
17:01 Apr 01, 2014
Jkt 232001
[Docket No. FDA–2013–N–0796]
AGENCY:
Food and Drug Administration,
HHS.
PO 00000
Frm 00052
Fmt 4703
Sfmt 4703
Notice.
The Food and Drug
Administration (FDA) is announcing
that a collection of information entitled
‘‘Testing Communications on Medical
Devices and Radiation-Emitting
Products’’ has been approved by the
Office of Management and Budget
(OMB) under the Paperwork Reduction
Act of 1995.
FOR FURTHER INFORMATION CONTACT: FDA
PRA Staff, Office of Operations, Food
and Drug Administration, 1350 Piccard
Dr., PI50–400B, Rockville, MD 20850,
PRAStaff@fda.hhs.gov.
SUPPLEMENTARY INFORMATION: On
December 20, 2013, the Agency
submitted a proposed collection of
information entitled ‘‘Testing
Communications on Medical Devices
and Radiation-Emitting Products’’ to
OMB for review and clearance under 44
U.S.C. 3507. An Agency may not
conduct or sponsor, and a person is not
required to respond to, a collection of
information unless it displays a
currently valid OMB control number.
OMB has now approved the information
collection and has assigned OMB
control number 0910–0678. The
approval expires on March 31, 2017. A
copy of the supporting statement for this
information collection is available on
the Internet at https://www.reginfo.gov/
public/do/PRAMain.
SUMMARY:
Dated: March 27, 2014.
Leslie Kux,
Assistant Commissioner for Policy.
[FR Doc. 2014–07325 Filed 4–1–14; 8:45 am]
BILLING CODE 4160–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2013–P–1379]
Determination That PREZISTA
(Darunavir) Tablets, 400 Milligrams,
Was Not Withdrawn From Sale for
Reasons of Safety or Effectiveness
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
III. Eligible Applicants
Incumbent TA grantees with award
expiration dates of 5/31/14.
VerDate Mar<15>2010
ACTION:
Notice.
The Food and Drug
Administration (FDA or the Agency) has
determined that PREZISTA (darunavir)
tablets, 400 milligrams (mg), was not
withdrawn from sale for reasons of
safety or effectiveness. This
determination will allow FDA to
approve abbreviated new drug
applications (ANDAs) for darunavir
tablets, 400 mg, if all other legal and
regulatory requirements are met.
SUMMARY:
E:\FR\FM\02APN1.SGM
02APN1
]]>Agencies
[Federal Register Volume 79, Number 63 (Wednesday, April 2, 2014)]
[Notices]
[Page 18558]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2014-07325]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2013-N-0796]
Agency Information Collection Activities; Announcement of Office
of Management and Budget Approval; Testing Communications on Medical
Devices and Radiation-Emitting Products
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is announcing that a
collection of information entitled ``Testing Communications on Medical
Devices and Radiation-Emitting Products'' has been approved by the
Office of Management and Budget (OMB) under the Paperwork Reduction Act
of 1995.
FOR FURTHER INFORMATION CONTACT: FDA PRA Staff, Office of Operations,
Food and Drug Administration, 1350 Piccard Dr., PI50-400B, Rockville,
MD 20850, PRAStaff@fda.hhs.gov.
SUPPLEMENTARY INFORMATION: On December 20, 2013, the Agency submitted a
proposed collection of information entitled ``Testing Communications on
Medical Devices and Radiation-Emitting Products'' to OMB for review and
clearance under 44 U.S.C. 3507. An Agency may not conduct or sponsor,
and a person is not required to respond to, a collection of information
unless it displays a currently valid OMB control number. OMB has now
approved the information collection and has assigned OMB control number
0910-0678. The approval expires on March 31, 2017. A copy of the
supporting statement for this information collection is available on
the Internet at https://www.reginfo.gov/public/do/PRAMain.
Dated: March 27, 2014.
Leslie Kux,
Assistant Commissioner for Policy.
[FR Doc. 2014-07325 Filed 4-1-14; 8:45 am]
BILLING CODE 4160-01-P
